et al., The Japanese Journal of Antibiotics, 74-1, Mar 2021 (Review) (Peer Reviewed)
Review of ivermectin for COVID-19. Authors note that Kitasato University's project was expanded in response to the results of Caly et al. which had left questions regarding in vivo
therapeutic levels, and the results of those studies were positive. Early in the pandemic, Kitasato University requested Merck to conduct clinical trials in Japan because they have priority for an expansion of ivermectin's indications, however Merck declined.
Since large companies have declined to study ivermectin for COVID-19, trials have been mostly doctor-initiated with relatively little funding. Authors discuss these, noting that the physicians involved are enthusiastic about avoiding bias, and strive to treat and prevent COVID-19 witn non-profit motives.
Authors discuss the trials, epidemiological data, and inaccurate statements made by certain authorities.
Authors note that regulations make it challenging for doctor-initiated trials to enroll many participants in a timely manner.
Authors conclude that ivermectin may turn out to be comparable to the benefits achieved from the discovery of penicillin - said to be one of the greatest discoveries of the twentieth century.
Authors include the nobel prize winning biochemist who discovered ivermectin, Satoshi Ōmura .
Yagisawa et al., 3/24/2021, peer-reviewed, 4 authors.